C. Ann Merrifield, Director at Lyra Therapeutics, Inc. (LYRA), bought 4,000 shares at $5.05 ($20K) on 2022-06-10, disclosed to the SEC on 2022-06-13.
Open-market purchase of $20k LYRA by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| FLXN | BUY | 2019-05-24 | $101K | — | Filing → |
| JNP | BUY | 2016-08-29 | $11K | — | Filing → |
| FLXN | BUY | 2016-06-16 | $13K | — | Filing → |